Original ArticlesCost-effectiveness of statins☆
Section snippets
Overview
We developed a decision-analytic model in which the costs and effectiveness of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and no pharmacologic therapy could be compared in both primary and secondary prevention scenarios. The medical and economic consequences of lipid-regulating therapy are described as a Markov process with 7 health states (described in the following) and annual cycles. Patients are assumed to receive the usual starting dose of each statin (atorvastatin 10
Cost-effectiveness of statins versus no drug therapy
Incremental cost-effectiveness ratios for the 5 statins versus no drug therapy for men and women are presented in Table III, Table IV, respectively. For all patient profiles, atorvastatin has the least cost for any given level of effectiveness, followed by simvastatin, fluvastatin, pravastatin, and lovastatin, respectively. In general, cost-effectiveness ratios are more favorable for men versus women, for secondary versus primary prevention, for higher versus lower pretreatment LDL levels, and
Discussion
In this study we have assessed the cost-effectiveness of statins in primary and secondary prevention of coronary heart disease. Our findings are consistent with previous assessments6 that have indicated that statin therapy is generally cost-effective for secondary prevention in men and in women with multiple risk factors, and for primary prevention in men with additional risk factors and in women with the highest risk profiles. Moreover, the addition of atorvastatin to the armamentarium has
Acknowledgements
We wish to express our thanks to Shelley Drowns, Elizabeth Hamel, and Robert LaGrange for their assistance in model design and development.
References (23)
- et al.
Direct medical costs of coronary artery disease in the United States
Am J Cardiol
(1998) - et al.
Task force 6. Cost-effectiveness of assessment and management of risk factors
J Am Coll Cardiol
(1996) - et al.
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
Atherosclerosis
(1997) - et al.
Representativeness of the Framingham risk model for coronary heart disease mortalitya comparison with a national cohort study
J Chron Dis
(1987) - et al.
Estimation of coronary heart disease risk in a French working population using a modified Framingham model
J Clin Epidemiol
(1994) - et al.
A model for evaluating the cost-effectiveness of cholesterol-lowering treatment
Int J Technol Assessment Health Care
(1992) - et al.
Forecasting coronary heart disease incidence, mortality, and cost
Am J Public Health
(1987) - et al.
Cost-effectiveness of drug therapy for hypercholesterolaemiaa review of the literature
PharmacoEcon
(1992) - et al.
Foundations of cost-effectiveness analysis for health and medical practices
N Engl J Med
(1977) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults
JAMA
(1993)
Sample designThird National Health and Nutrition Examination Survey
Vital Health Stat 2
Cited by (72)
Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States
2015, International Journal of CardiologyCitation Excerpt :The costs of these side effects are much less than costs for FH screening and CVD or stroke treatment, so they were estimated as a continual annual cost for statin users, based on prices for common over-the-counter treatments from an online pharmacy website, drugstore.com. Because serious events are rare, costs for these events were not included [39,45]. Further, 46% is a high estimate for the proportion of statin-users who will report adverse events, and both the cost of statin medication and adverse events are varied in sensitivity analyses to address the possibility of higher costs.
The effectiveness and cost of single and multi-factorial cardiovascular risk factor modification to guideline targets in type 2 diabetes
2012, Primary Care DiabetesCitation Excerpt :The LIP2687 is directly based on the Framingham study equations outlined by D’Agostino et al., and Markov models based on the same risk equations have previously been published. Results from other applications of the LIP2687 model have also been published [21,23,24]. Descriptive statistics for the quantitative variables (age, height, weight, systolic blood pressure, HbA1C, total cholesterol and HDL-C) and categorical variables (sex, ethnic group, history of coronary heart disease and smoking status) for the baseline population were computed using Microsoft Excel (2007).
- ☆
This study was supported by Parke-Davis Pharmaceutical Research, a division of Warner-Lambert Company, Ann Arbor, Michigan, and Pfizer, Inc., New York, New York.